FDA Reviewing Roche Holding AG, Novartis AG Drug Risk Plans

Bookmark and Share

WASHINGTON, May 6 (Reuters) - The U.S. Food and Drug Administration said Wednesday it is reviewing risk management plans by Novartis AG and Roche Holding AG for transplant drugs linked to birth defects.

MORE ON THIS TOPIC